Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~Follow-on participants of V72P12:~Healthy toddlers who completed Study V72P12, aged:~* 12 months or older - Groups 1a, 2a, 3a, 4~* 18 months (0/ +29 days window) - Groups 1b, 2b, 3b~* 24 months (0/ +29 days window) - Groups 1c, 2c, 3c~Naive subjects newly enrolled:~* Group 5: healthy 18-month-old toddlers (0/ +29 days window)~* Group 6: healthy 24-month-old toddlers (0/ +29 days window)~Exclusion Criteria:~* History of any meningococcal B vaccine administration (only for groups 5 and 6);~* Previous ascertained or suspected disease caused by N. meningitidis;~* History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;~* Significant acute or chronic infection within the previous 7 days or axillary temperature major or equal to 38 degrees within the previous day~* Antibiotics within 6 days prior to enrollment;~* Any serious chronic or progressive disease;~* Known or suspected impairment or alteration of the immune system;~* Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- B+R246_12 (Type: EXPERIMENTAL): Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
- B+R246_18 (Type: EXPERIMENTAL): Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
- B+R246_24 (Type: EXPERIMENTAL): Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
- B246_12 (Type: EXPERIMENTAL): Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
- B246_18 (Type: EXPERIMENTAL): Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.
- B246_24 (Type: EXPERIMENTAL): Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.
- B+R234_12 (Type: EXPERIMENTAL): Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.
- B+R234_18 (Type: EXPERIMENTAL): Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
- B+R234_24 (Type: EXPERIMENTAL): Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
- B12 14 (Type: EXPERIMENTAL): Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.
- B18 20 (Type: EXPERIMENTAL): Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.
- B24 26 (Type: EXPERIMENTAL): Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).